Comments about the editorial by Bénédicte Mugnier and Jean Roudier entitled "Factors predicting responsiveness to anti-TNFalpha therapy in patients with rheumatoid arthritis: using biotherapies rationally"

Joint Bone Spine. 2005 Jul;72(4):346-7; author reply 347-8. doi: 10.1016/j.jbspin.2005.01.004. Epub 2005 Mar 24.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / blood
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / genetics
  • Gene Expression
  • Genetic Markers
  • Humans
  • Infliximab
  • Polymorphism, Genetic
  • Treatment Outcome
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / genetics
  • Tumor Necrosis Factor-alpha / metabolism

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Genetic Markers
  • Tumor Necrosis Factor-alpha
  • Infliximab